TNF and uveitis: Conversely, the APTITUDE trial enrolled 21 pediatric patients with anti-TNF-α refractory JIA-associated uveitis and found that only 33% met the resolution of ocular inflammation by week 12 after subcutaneous tocilizumab treatment (Ramanan et al., 2020a).